Caricamento...

Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia (CML). Imatinib at a dose of 400 mg/day is considered the standard treatment for all newly diagnosed chronic phase CML. Follow-up on the pivotal International Randomized Study of I...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hematol Oncol Clin North Am
Autori principali: Jabbour, Elias, Parikh, Sameer A., Kantarjian, Hagop, Cortes, Jorge
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428141/
https://ncbi.nlm.nih.gov/pubmed/22054730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2011.09.004
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !